Payment overview · 2025
General Payments
$6,588.16
41 reported records · 10 companies
Healthcare provider profile · identity verified
Alexandra Ingram
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIAMI, FL · NPI 1730843194
Verified facts
What the public records show
CMS Open Payments records show Alexandra Ingram received $6,588.16 in general payments during 2025 across 41 reported records.
ABBVIE INC. accounted for 58.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Inbrija, Ingrezza, Nuplazid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Nuplazid by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Gocovri by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INBRIJA as an associated drug or biological on 4307 records involving 2211 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Inbrija by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xeomin as an associated drug or biological on 8663 records involving 4073 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xeomin by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ingrezza by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,821.98 | 58.0% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,133.76 | 32.4% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $183.11 | 2.8% | 3 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $153.55 | 2.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $122.55 | 1.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $62.65 | 0.9% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $53.71 | 0.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.27 | 0.3% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.51 | 0.3% | 1 | 2025 |
| Cala Health, Inc. | Unresolved — no canonical attribution shown | $17.07 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,628.03 | 12 |
| Consulting Fee | $2,582.25 | 2 |
| Food and Beverage | $1,332.88 | 26 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $3,821.98 | 14 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $2,133.76 | 14 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $183.11 | 3 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $153.55 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $122.55 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $62.65 | 1 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Cala kIQ Normalized: cala kiq |
Device | Cala Health, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INBRIJA inbrija |
2025 | Inbrija | 2024 | 70 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 66 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 190 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
127 | 63 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
190 | 35 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
125 | 26 |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | INBRIJA open payments reported associated product |
CMS Open Payments — General Payments 4307 supporting records · 2211 recipient NPIs · example record 1232555387 |
Inbrija · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | Xeomin open payments reported associated product |
CMS Open Payments — General Payments 8663 supporting records · 4073 recipient NPIs · example record 1232555385 |
Xeomin · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 1243 | 475 |
| Rytary | Carbidopa/Levodopa | 325 | 88 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 301 | 101 |
| Clonazepam | Clonazepam | 241 | 80 |
| Donepezil Hcl | Donepezil Hcl | 227 | 79 |
| Nuplazid | Pimavanserin Tartrate | 190 | 35 |
| Amantadine | Amantadine Hcl | 166 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 62 |
| Trazodone Hcl | Trazodone Hcl | 144 | 55 |
| Botox | Onabotulinumtoxina | 127 | 63 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 51 |
| Rivastigmine | Rivastigmine Tartrate | 126 | 38 |
| Gocovri | Amantadine Hcl | 125 | 26 |
| Primidone | Primidone | 119 | 44 |
| Rasagiline Mesylate | Rasagiline Mesylate | 118 | 51 |
| Baclofen | Baclofen | 117 | 45 |
| Mirtazapine | Mirtazapine | 101 | 51 |
| Gabapentin | Gabapentin | 96 | 37 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 36 |
| Sertraline Hcl | Sertraline Hcl | 93 | 32 |
| Neupro | Rotigotine | 90 | 26 |
| Selegiline Hcl | Selegiline Hcl | 87 | 18 |
| Ongentys | Opicapone | 85 | 19 |
| Alprazolam | Alprazolam | 75 | 23 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 71 | 23 |
| Inbrija | Levodopa | 70 | 17 |
| Ingrezza | Valbenazine Tosylate | 66 | 13 |
| Rivastigmine | Rivastigmine | 66 | 22 |
| Bupropion Xl | Bupropion Hcl | 63 | 18 |
| Memantine Hcl | Memantine Hcl | 55 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 46 | 12 |
| Entacapone | Entacapone | 44 | 23 |
| Lorazepam | Lorazepam | 40 | 13 |
| Propranolol Hcl | Propranolol Hcl | 40 | 20 |
| Droxidopa | Droxidopa | 37 | suppressed |
| Crexont | Carbidopa/Levodopa | 35 | 18 |
| Myrbetriq | Mirabegron | 35 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | 15 |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Myobloc | Rimabotulinumtoxinb | 30 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Topiramate | Topiramate | 28 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 27 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 26 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Nourianz | Istradefylline | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Austedo Xr | Deutetrabenazine | 15 | suppressed |
| Xeomin | Incobotulinumtoxina | 14 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,588.16 · 41 records | ABBVIE INC. | AUSTEDO XR, Apokyn, Cala kIQ, INBRIJA, INGREZZA, NOVOSORB BTM, NUPLAZID, PERCEPT PC BRAINSENSE, VYALEV, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error